FirstWord is a company belonging to one of the most colossal global healthcare knowledge networks. The company offers its customers a wealthy collection of reports covering various sectors of the worldwide pharmaceutical market and, thereby, providing them with unparalleled knowledge to get a leg up on other competitors in the sphere.

Prepared using the rich and reliable information sources, FirstWord’s reports grant access to the unrivalled quantitative and qualitative intelligence on the pharmaceutical industry; offer insightful market analyses; clearly describe predominant development trends; characterize the foremost factors having an effect on the market; and discuss the most burning issues having relation to the specific industry.

Research Reports By FirstWord

Found 345 publications
Cancer Immunotherapy: Payer Insight US$ 7,495.00 Oct, 2015
Multiple Sclerosis: KOL Insight US$ 7,495.00 Oct, 2015
Tomorrow’s MSLs US$ 595.00 Oct, 2015
Hepatitis C: KOL Insight US$ 7,495.00 Sep, 2015
Type 2 Diabetes Mellitus: KOL Insight US$ 7,495.00 Jul, 2015
Charting MSL Activity and Performance US$ 595.00 Jun, 2015 58 pages
The Future of Biosimilars 2015 US$ 2,100.00 Jun, 2015 120 pages
Clinical Trial Design for Commercial Success US$ 595.00 Jun, 2015 72 pages
Breast Cancer: KOL Insight US$ 7,495.00 May, 2015
1 2 3 4 5 ... 7
Skip to top

News & Press-Releases by FirstWord